Summary
Boston Scientific Corporation's 2004 10-K report highlights a year of significant growth, driven primarily by the strong performance of its TAXUS® Express 2™ paclitaxel-eluting coronary stent system. Net sales surged by 62% to $5.62 billion, with the TAXUS stent system alone accounting for 38% of total net sales, underscoring its critical role in the company's revenue. The company is strategically positioned to capitalize on the expanding drug-eluting stent market, which it anticipates will constitute the majority of the coronary stent market in the coming years. Boston Scientific is also actively investing in its research and development pipeline, pursuing next-generation technologies and expanding into new therapeutic areas such as neuromodulation through its acquisition of Advanced Bionics Corporation. While the company faces ongoing patent litigation and competitive pressures, its focus on innovation, product diversity, and operational excellence aims to sustain its market leadership.
Key Highlights
- 1Significant revenue growth of 62% in 2004, reaching $5.62 billion, largely driven by the TAXUS Express 2™ drug-eluting coronary stent system.
- 2The TAXUS stent system is a key revenue driver, accounting for 38% of total net sales in 2004.
- 3Expansion into the neuromodulation market through the acquisition of Advanced Bionics Corporation.
- 4Increased investment in R&D, particularly in next-generation stent platforms and new technologies across various therapeutic areas.
- 5Strategic focus on innovation, clinical excellence, product diversity, and operational efficiency as core business strategies.
- 6The company is facing multiple patent litigations with competitors, particularly in the coronary stent market.
- 7International sales accounted for 37% of net sales, with Europe and Inter-Continental markets showing strong growth.